Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS Astellas Vice Deputy Chairman Ishii Says Company R&D Strategy Focused on Personalized Medicine
March 22, 2012
-
REGULATORY Council Meeting Considers Working Team to Explore Directions for Drug Distribution Improvement
March 21, 2012
-
ORGANIZATION Asia Partnership Conference Starts Talks for Early NDA Approval at Inauguration Meeting in Tokyo
March 19, 2012
-
BUSINESS Break of Day－Working to Optimize Settai Practices, Increase Financial Transparency: 1
March 19, 2012
-
BUSINESS Eli Lilly Japan Looks at Double-Digit Growth Despite Large Price Cuts in 2 Mainstay Drugs: President Zulueta
March 16, 2012
-
ORGANIZATION JPMA Compiles Policies for Transparency in Patient Group Relationships, Disclosure for States of Donations
March 15, 2012
-
BUSINESS Sawai’s Next Midterm Management Plan Aims to Create a “Muscular Company”: Pres. Sawai
March 14, 2012
-
BUSINESS Pfizer Reports 19% Boost in Sales in FY2011, “Continued Growth Possible” After Re-Pricing
March 13, 2012
-
REGULATORY Convincing Data Needed to Perpetuate Premium for New Drug Development: Mr Yoshida of MED
March 13, 2012
-
BUSINESS Sanofi-aventis Nichi-Iko Obtains Approval for Allegra Generic While Patent Dispute Continues
March 12, 2012
-
BUSINESS 20 Companies Review Risk Countermeasures After Earthquake, Novartis Looks into MR Standards of Behavior: Jiho Survey
March 9, 2012
-
BUSINESS Daiichi Sankyo to Integrate Global, Japan Business Management Functions into Four-Division Structure
March 8, 2012
-
ORGANIZATION Wholesale Industry FTC to “Watch Closely” How Drug Makers Respond to Tougher Rules on Business Entertaining
March 7, 2012
-
BUSINESS Eisai to See 11%+, Lilly Japan 8-9% Average Price Reduction in FY2012 NHI Price Revision: Jiho Survey
March 6, 2012
-
REGULATORY 702 Products Including DPP-4 Inhibitors to Be Eligible for New Drug Premium in April
March 5, 2012
-
REGULATORY Private-Sector Members of Strategy Council Call for Early Establishment of Drug Discovery Support Organization
March 5, 2012
-
ORGANIZATION KSLION to Stimulate Innovation in Life Science in Japan: Prof. Y. Natsumeda
March 5, 2012
-
BUSINESS Medipal Group to Determine Profitability with Each Customer: Next President Shuichi Watanabe
March 2, 2012
-
BUSINESS DSP to Acquire Boston Biomedical, US Bioventure Specializing in Oncology
March 1, 2012
-
BUSINESS Pfizer Japan to Set Up Rare Disease Division
February 29, 2012
ページ
As Japan approaches the Fiscal System Council’s “autumn recommendation,” a notable shift is taking shape. The Ministry of Finance (MOF),…
Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…